Literature DB >> 23902289

A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study.

Eyal Greenberg1, Michal J Besser, Eytan Ben-Ami, Ronnie Shapira-Frommer, Orit Itzhaki, Dragoslav Zikich, Daphna Levy, Adva Kubi, Eran Eyal, Amir Onn, Yehudit Cohen, Iris Barshack, Jacob Schachter, Gal Markel.   

Abstract

CONTEXT: Quantification of circulating microRNAs (miRNAs) has recently become feasible and reliable, with most efforts focusing on miRNAs overexpressed by cancer cells.
OBJECTIVE: Identification of a characteristic circulating miRNAs profile in melanoma patients.
METHODS: We conducted a pilot study comprised of unbiased qPCR comparison of serum miRNA profiles between metastatic melanoma patients and healthy donors.
RESULTS: Loss of two normal serum-miRNAs, miR-29c and miR-324-3p, is highly indicative of metastatic melanoma. Hierarchical clustering analysis supported the results and clearly distinguished melanoma patients from healthy donors, metastatic colon and renal cancer patients. DISCUSSION AND
CONCLUSIONS: This approach is independent of tumor heterogeneity and is expected to have superior biomarker performances.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23902289     DOI: 10.3109/1354750X.2013.816777

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  20 in total

Review 1.  Circulating epigenetic biomarkers in melanoma.

Authors:  Yu Xin; Zheng Li; Matthew T V Chan; William Ka Kei Wu
Journal:  Tumour Biol       Date:  2015-12-11

2.  Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients.

Authors:  Nathaniel H Fleming; Judy Zhong; Inês Pires da Silva; Eleazar Vega-Saenz de Miera; Bobbi Brady; Sung Won Han; Doug Hanniford; Jinhua Wang; Richard L Shapiro; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

Review 3.  Biomarkers in melanoma: where are we now?

Authors:  Douglas B Johnson; Ryan J Sullivan
Journal:  Melanoma Manag       Date:  2014-12-04

Review 4.  Cell-free microRNAs in blood and other body fluids, as cancer biomarkers.

Authors:  Blanca Ortiz-Quintero
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

5.  miR-337 can be a key negative regulator in melanoma.

Authors:  Wanan Xiao; Enyang Yao; Wei Zheng; Feng Tian; Lijie Tian
Journal:  Cancer Biol Ther       Date:  2017-05-12       Impact factor: 4.742

Review 6.  Regulation of cancer metastasis by cell-free miRNAs.

Authors:  Maša Alečković; Yibin Kang
Journal:  Biochim Biophys Acta       Date:  2014-10-28

Review 7.  Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives.

Authors:  Hisashi Kanemaru; Yukari Mizukami; Akira Kaneko; Ikko Kajihara; Satoshi Fukushima
Journal:  Curr Treat Options Oncol       Date:  2022-03-17

Review 8.  Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.

Authors:  Sharon K Huang; Dave S B Hoon
Journal:  Mol Oncol       Date:  2015-12-17       Impact factor: 6.603

9.  MiR-135 post-transcriptionally regulates FOXO1 expression and promotes cell proliferation in human malignant melanoma cells.

Authors:  Jian-Wen Ren; Zhang-Jun Li; Chen Tu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

10.  The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Authors:  Mitchell S Stark; Kerenaftali Klein; Benjamin Weide; Lauren E Haydu; Annette Pflugfelder; Yue Hang Tang; Jane M Palmer; David C Whiteman; Richard A Scolyer; Graham J Mann; John F Thompson; Georgina V Long; Andrew P Barbour; H Peter Soyer; Claus Garbe; Adrian Herington; Pamela M Pollock; Nicholas K Hayward
Journal:  EBioMedicine       Date:  2015-05-12       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.